1d
GlobalData on MSNAstraZeneca lung cancer therapy Imfinzi recommended for EU approvalThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...
Biopharmaceutical giant AstraZeneca has announced it is introducing advanced diagnostic testing for lung cancer in Kenya and ...
11d
News Medical on MSNAstraZeneca receives positive NICE recommendations for lung cancer treatmentAstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...
Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...
1d
Daily Independent on MSNAstraZeneca reaffirms commitment to cancer care on World Cancer Day 2025 with innovative solutionsJOHANNESBURG: In recognition of World Cancer Day 2025, AstraZeneca reaffirms its commitment to advancing early detection, ...
Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...
Panjim: The Goa Health Department, alongside AstraZeneca and Qure.ai, is launching multiple initiatives to improve cancer ...
AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy ...
The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...
CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.
AstraZeneca has reaffirmed its commitment to transforming cancer care in Africa, unveiling new initiatives aimed at enhancing early detection, treatment, and patient support as part of World Cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results